EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aberrant type 2 dopamine and mu-opioid receptor availability in autism spectrum disorder

Tuomo Noppari iD, Jouni Tuisku, Lasse Lukkarinen, Pekka Tani, Nina Lindberg, Emma Saure, Hannu Lauerma, Jari Tiihonen, Jussi Hirvonen, Semi Helin, Johan Rajander, Juha Salmi und 1 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026-02 · 53 (3) · 2069-2082

DOI: 10.1007/s00259-025-07620-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 18.10.2025. Verfasst von Tuomo Noppari und 12 weiteren Autor:innen. Beteiligte Einrichtung: Turku PET Centre, University of Turku, Turku, Finland. tuomo.noppari@hus.fi. Hauptthemen laut MEDLINE: Receptors, Opioid, mu, Autism Spectrum Disorder, Receptors, Dopamine D2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Helsinki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Opioid and dopamine receptor systems are implicated in the pathoetiology of autism, but in vivo human brain imaging evidence for their role remains elusive.

Methods

Here, we investigated regional type 2 dopamine and mu-opioid receptor (D2R and MOR, respectively) availabilities and regional interactions between the two neuromodulatory systems associated with autism spectrum disorder (ASD). In vivo positron emission tomography (PET) with radioligands [11 C]raclopride (D2R) and [11 C]carfentanil (MOR) was carried out in 16 adult males with high functioning ASD and 24 age and sex matched controls. A whole brain voxel-wise analysis was tested with Student´s t-test and regional group differences in D2R and MOR receptor availabilities as total and separate were tested with linear mixed models also examining the associations between regional receptor availabilities with correlations.

Results

There were no group differences in whole-brain voxel-wise analysis of D2R, but ROI analysis revealed a lower overall mean availability in striatum of the ASD compared to controls. Post hoc regional analysis revealed reduced D2R availability in nucleus accumbens and globus pallidus of the ASD group. The whole-brain voxel-wise analysis of MOR revealed cuneal/precuneal up-regulation in the ASD group, but there was no overall group difference in the ROI analysis for MOR. MOR down-regulation was observed in the hippocampi of the ASD group in a post hoc analysis. Regional correlations between D2R and MOR availabilities were weaker in the ASD group versus control group in the amygdala and nucleus accumbens.

Conclusions

These alterations may translate to disrupted modulation of social motivation and reward in ASD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Opioid, muAutism Spectrum DisorderReceptors, Dopamine D2HumansMalePositron-Emission TomographyAdultYoung AdultCase-Control StudiesBrainRacloprideFentanyl

Stichwörter der Autor:innen

AutismD2RDopamineMOROpioidPositron emission tomography

Substanzen

Receptors, Opioid, muReceptors, Dopamine D2carfentanilRacloprideFentanyl

Autor:innen und Institutionen

  • Turku PET Centre, University of Turku, Turku, Finland. tuomo.noppari@hus.fi.
  • Turku University Hospital, Turku, Finland. tuomo.noppari@hus.fi.
  • Department of Psychiatry, Helsinki University Hospital, Helsinki, Finland. tuomo.noppari@hus.fi.
  • Turku PET Centre, University of Turku, Turku, Finland.
  • Turku University Hospital, Turku, Finland.
  • Department of Psychiatry, Helsinki University Hospital, Helsinki, Finland.

ORCID-Profile: Tuomo Noppari

Förderung

  • University of Helsinki

Zitieren

APA

Noppari, T., Tuisku, J., Lukkarinen, L., Tani, P., Lindberg, N., Saure, E., Lauerma, H., Tiihonen, J., Hirvonen, J., Helin, S., Rajander, J., Salmi, J., & Nummenmaa, L. (2026). Aberrant type 2 dopamine and mu-opioid receptor availability in autism spectrum disorder. European Journal of Nuclear Medicine and Molecular Imaging, 53(3), 2069-2082. https://doi.org/10.1007/s00259-025-07620-5

Vancouver

Noppari T, Tuisku J, Lukkarinen L, Tani P, Lindberg N, Saure E, et al. Aberrant type 2 dopamine and mu-opioid receptor availability in autism spectrum disorder. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(3):2069-2082. doi:10.1007/s00259-025-07620-5

BibTeX
@article{Noppari2026,
  author = {Noppari, Tuomo and Tuisku, Jouni and Lukkarinen, Lasse and Tani, Pekka and Lindberg, Nina and Saure, Emma and Lauerma, Hannu and Tiihonen, Jari and Hirvonen, Jussi and Helin, Semi and Rajander, Johan and Salmi, Juha and Nummenmaa, Lauri},
  title = {Aberrant type 2 dopamine and mu-opioid receptor availability in autism spectrum disorder},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {3},
  pages = {2069--2082},
  doi = {10.1007/s00259-025-07620-5}
}
Kostenlos starten →